What biomarker testing is recommended for metastatic Prostate Cancer

Biomarker Testing for Metastatic Prostate Cancer

Based on current medical guidelines, here's what testing is recommended for patients with metastatic prostate cancer:

PRIMARY TESTING RECOMMENDATIONS

According to NCCN Guidelines for Prostate Cancer (2.2026), the following biomarker testing is recommended for patients with metastatic disease:

1. DNA Damage Response (HRR) Gene Testing

Multigene tumor testing is recommended to look for alterations in genes responsible for DNA repair, including:

• BRCA1 and BRCA2 (especially important - may predict better response to PARP inhibitors)
• ATM, PALB2, FANCA, RAD51D, CHEK2, and CDK12

Why this matters: These mutations can make your cancer vulnerable to specific targeted therapies called PARP inhibitors, which prevent cancer cells from repairing damaged DNA.

2. Mismatch Repair (MMR) and Microsatellite Instability (MSI) Testing

• Testing for MSI-H (high microsatellite instability) or dMMR (mismatch repair deficiency)
• Should use next-generation sequencing assays validated for prostate cancer

Why this matters: If you have MSI-H or dMMR, you may be eligible for immunotherapy with pembrolizumab (Keytruda), which helps your immune system fight cancer cells.

3. Tumor Mutational Burden (TMB) Testing

• Measures the total number of DNA changes in your cancer cells

Why this matters: High TMB may indicate better response to certain immunotherapies.

HOW TESTING IS DONE

Preferred approach: A biopsy of your metastatic lesion (tumor tissue that has spread) for both histologic examination and molecular testing.

Alternative option: If a biopsy is unsafe or not possible, a plasma circulating tumor DNA (ctDNA) test (blood test) can be used. However, this is less reliable when PSA is undetectable, so timing matters.

ADDITIONAL TESTING TO CONSIDER

According to expert guidance from the Cancer Patient Lab webinars, you should also discuss:

• Genetic testing for inherited mutations (germline testing) - identifies actionable treatments for about 20% of patients
• Liquid biopsies - blood tests that can monitor disease response over time
• Imaging biomarkers - PSMA-PET scans can help assess disease burden and predict response to certain radiopharmaceutical treatments

IMPORTANT POST-TEST STEP

If your testing finds pathogenic (disease-causing) mutations in genes like BRCA1, BRCA2, ATM, PALB2, or CHEK2, genetic counseling is recommended. This is important because these mutations may also be present in your normal cells (inherited), which has implications for your family members.

---

QUESTIONS TO ASK YOUR ONCOLOGIST

1. "Should I have tumor tissue testing, blood testing, or both?" - Your doctor will determine what's most appropriate based on your specific situation.

2. "Which specific biomarkers should be tested in my case?" - Not all tests are needed for everyone; your oncologist will prioritize based on your cancer stage and treatment options.

3. "If mutations are found, what treatment options does that open up for me?" - Understanding how results guide treatment decisions is crucial.

4. "Do I need genetic counseling if mutations are found?" - This helps you understand implications for your family.

5. "How will you use these results to guide my treatment plan?" - Ensures the testing will actually inform your care decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.